D1553

PreclinicalSmall molecule

IInxMed (Shanghai) Co., Ltd.

D1553 is one of 37 small molecule programs targeting Solid Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

Solid TumorPreclinical

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

DATROWAY

Daiichi Sankyo

Preclinical

1 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 4

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 5

Navmi

SSummit Therapeutics

Preclinical

1 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 8

Tulmimetostat

Novartis

Preclinical

1 9

Carboplatin AUC-5

Merck & Co.

Preclinical

1 10

Soc

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalActive, not recruiting

Solid Tumor

NCT06166836

Clinical

Trials by Indication[1]

Solid Tumor1 trial

A Phase 1b/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combined With IN10018 in Subjects With Locally Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Active, not recruiting·IInxMed (Shanghai) Co., Ltd.·Preclinical·NCT06166836·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for D1553. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D1553 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D1553. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — InxMed (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInxMed (Shanghai) Co., Ltd.

D1553

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News